Home LiteratureArticle Details
PMID: 23108356 Published · ppublish English Journal Article Review

Mini-chaperones: potential immuno-stimulators in vaccine design.

Human vaccines & immunotherapeutics ·Vol. 9 ·No. 1 ·2013-01-00 ·Pages 153-61

Bolhassani A, Rafati S

Abstract

The immunogenic properties of heat shock proteins (HSPs) have prompted investigations into their application as immuno-modulatory agents. HSPs have been used as potent adjuvants in immunotherapy of cancer and infectious diseases. Some studies showed that immune activities reside within N- or C-terminal fragments of HSPs. These small fragments are sufficient to link peptides, to bind and be taken up by the receptors CD91 and scavenger receptor type A on antigen presenting cells (APCs). Thus, these mini-chaperones can be used in immunotherapy of tumors and vaccine development. The data clearly demonstrated the potential of using HSP fragments as a possible adjuvant to augment CTL response against infectious diseases. Some HSP domains have been shown to inhibit endothelial cell growth, angiogenesis or tumor growth. In this review, we describe the immuno-stimulatory activities of various mini-chaperones in development of different vaccine strategies (DNA-based vaccine and protein/peptide-based vaccines).

Keywords
cancer heat shock protein immuno-adjuvant infectious disease mini-chaperone vaccine
MeSH Terms
Adjuvants, Immunologic/administration & dosage,genetics Heat-Shock Proteins/administration & dosage,genetics Peptide Fragments/administration & dosage,genetics Vaccines/administration & dosage,immunology
Chemicals
Adjuvants, Immunologic Heat-Shock Proteins Peptide Fragments Vaccines
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Bolhassani Azam
Molecular Immunology and Vaccine Research Lab., Pasteur Institute of Iran, Tehran, Iran. azam_bolhassani@yahoo
Rafati Sima
References (70)
70 references, click to expand
  1. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Clin Cancer Res. 2008 Jan 1;14(1):178-87 PMID: 18172269
  2. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Vaccine. 2006 Apr 12;24(16):3321-31 PMID: 16472546
  3. Hsp-based tumor vaccines: state-of-the-art and future directions.
    Curr Opin Mol Ther. 2007 Aug;9(4):385-91 PMID: 17694451
  4. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70.
    J Immunol. 2002 Sep 1;169(5):2422-9 PMID: 12193710
  5. A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70.
    FEMS Immunol Med Microbiol. 2011 Mar;61(2):189-96 PMID: 21204994
  6. Heat shock proteins HSP70 and GP96: structural insights.
    Cancer Immunol Immunother. 2006 Mar;55(3):339-46 PMID: 16032399
  7. The immunization of A2/K(b) transgenic mice with the KMP11-HSP70 fusion protein induces CTL response against human cells expressing the T. cruzi KMP11 antigen: identification of A2-restricted epitopes.
    Mol Immunol. 2001 Aug;38(4):279-87 PMID: 11566321
  8. The N-terminal fragment of GRP94 is sufficient for peptide presentation via professional antigen-presenting cells.
    Int Immunol. 2006 Jul;18(7):1147-57 PMID: 16772370
  9. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Vaccine. 2008 Jun 19;26(26):3362-70 PMID: 18471945
  10. Co-administration of GP96 and Her2/neu DNA vaccine in a Her2 breast cancer model.
    Cell Stress Chaperones. 2010 Nov;15(6):977-84 PMID: 20544406
  11. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth.
    J Exp Med. 1998 Dec 21;188(12):2349-56 PMID: 9858521
  12. Heat shock protein as molecular targets for breast cancer therapeutics.
    J Breast Cancer. 2011 Sep;14(3):167-74 PMID: 22031796
  13. N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.
    Cell Stress Chaperones. 2010 Sep;15(5):631-8 PMID: 20224916
  14. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24.
    J Immunol. 1996 Jan 15;156(2):873-9 PMID: 8543845
  15. The heat-shock protein receptors: some answers and more questions.
    Tissue Antigens. 2004 Oct;64(4):442-51 PMID: 15361121
  16. Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming.
    Eur J Immunol. 1992 Jun;22(6):1365-72 PMID: 1601031
  17. Different spectra of therapeutic vaccine development against HPV infections.
    Hum Vaccin. 2009 Oct;5(10):671-89 PMID: 19684468
  18. The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis.
    J Neuroimmunol. 1996 Apr;65(2):143-53 PMID: 8964896
  19. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice.
    Vaccine. 2011 Aug 11;29(35):5959-62 PMID: 21722685
  20. Enhancement of DNA vaccine potency by linkage of Plasmodium falciparum malarial antigen gene fused with a fragment of HSP70 gene.
    Vaccine. 2005 Jan 19;23(9):1114-25 PMID: 15629354
  21. GP96 C-terminal improves Her2/neu DNA vaccine.
    J Gene Med. 2010 Apr;12(4):345-53 PMID: 20232284
  22. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Exp Parasitol. 2011 Mar;127(3):627-36 PMID: 21187087
  23. Cloning, expression, and immunogenicity of novel fusion protein of Mycobacterium tuberculosis based on ESAT-6 and truncated C-terminal fragment of HSP70.
    Biologicals. 2011 May;39(3):143-8 PMID: 21388826
  24. DNA immunization as an efficient strategy for vaccination.
    Avicenna J Med Biotechnol. 2009 Jul;1(2):71-88 PMID: 23407787
  25. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70.
    Int Immunol. 2001 Oct;13(10):1233-42 PMID: 11581168
  26. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.
    Cell Stress Chaperones. 2011 Jul;16(4):449-57 PMID: 21359667
  27. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Vaccine. 2007 May 22;25(21):4159-69 PMID: 17395340
  28. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Scand J Immunol. 2012 Jan;75(1):27-37 PMID: 21916914
  29. Cross-reactive mycobacterial and self hsp60 epitope recognition in I-A(g7) expressing NOD, NOD-asp and Biozzi AB/H mice.
    J Autoimmun. 2002 Mar;18(2):139-47 PMID: 11908946
  30. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments.
    J Immunol. 2005 Jan 1;174(1):195-204 PMID: 15611241
  31. T cells and autoantibodies to human HSP70 in type 1 diabetes in children.
    J Autoimmun. 2003 Jun;20(4):313-21 PMID: 12791317
  32. Structure and function: heat shock proteins and adaptive immunity.
    J Immunol. 2007 Aug 15;179(4):2035-40 PMID: 17675458
  33. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation.
    Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1662-7 PMID: 18216248
  34. Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.
    Expert Rev Vaccines. 2011 Nov;10(11):1553-68 PMID: 22043955
  35. In vivo activities of GroEL minichaperones.
    Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9861-6 PMID: 9707566
  36. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83.
    Mol Immunol. 1999 Dec;36(17):1131-9 PMID: 10698315
  37. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein.
    Mol Biol Rep. 2010 Jul;37(6):2877-83 PMID: 19813102
  38. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.
    Mol Immunol. 2013 Jan;53(1-2):149-60 PMID: 22926003
  39. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice.
    World J Gastroenterol. 2005 May 21;11(19):2858-63 PMID: 15902719
  40. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin.
    Immunity. 2001 Mar;14(3):303-13 PMID: 11290339
  41. Molecular chaperones in mammary cancer growth and breast tumor therapy.
    J Cell Biochem. 2012 Apr;113(4):1096-103 PMID: 22105880
  42. Autoimmune and inflammatory mechanisms in atherosclerosis.
    Annu Rev Immunol. 2004;22:361-403 PMID: 15032582
  43. Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells.
    Blood. 2009 Mar 26;113(13):3008-16 PMID: 19018093
  44. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity.
    Biochem Soc Trans. 2004 Aug;32(Pt 4):629-32 PMID: 15270693
  45. Recent advances in heat shock protein-based cancer vaccines.
    Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):22-7 PMID: 16481277
  46. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Cell Stress Chaperones. 2011 Jan;16(1):41-8 PMID: 20730610
  47. Heat-shock proteins as powerful weapons in vaccine development.
    Expert Rev Vaccines. 2008 Oct;7(8):1185-99 PMID: 18844593
  48. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis.
    Vaccine. 2008 Mar 4;26(10):1387-96 PMID: 18272260
  49. Targeting the ubiquitin system in cancer therapy.
    Nature. 2009 Mar 26;458(7237):438-44 PMID: 19325623
  50. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.
    Indian J Med Res. 2009 Nov;130(5):533-41 PMID: 20090101
  51. Dual role of heat shock proteins as regulators of apoptosis and innate immunity.
    J Innate Immun. 2010;2(3):238-47 PMID: 20375559
  52. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
    Cancer Immunol Immunother. 2005 Sep;54(9):891-7 PMID: 15776283
  53. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.
    Eur J Immunol. 2007 Mar;37(3):675-85 PMID: 17304628
  54. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    J Immunol. 2003 Oct 15;171(8):4054-61 PMID: 14530326
  55. Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70.
    Proc Natl Acad Sci U S A. 1985 Oct;82(19):6455-9 PMID: 3931075
  56. Fusion expression of major antigenic segment of JEV E protein-hsp70 and the identification of domain acting as adjuvant in hsp70.
    Vet Immunol Immunopathol. 2006 Oct 15;113(3-4):288-96 PMID: 16859755
  57. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  58. Facets of heat shock protein 70 show immunotherapeutic potential.
    Immunology. 2003 Sep;110(1):1-9 PMID: 12941135
  59. Heat shock proteins as immunological carriers and vaccines.
    EXS. 1996;77:451-65 PMID: 8856990
  60. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response.
    Cell Stress Chaperones. 2005 Autumn;10(3):221-9 PMID: 16184767
  61. Heterologous expression of FMDV immunodominant epitopes and HSP70 in P. pastoris and the subsequent immune response in mice.
    Vet Microbiol. 2007 Oct 6;124(3-4):256-63 PMID: 17548173
  62. DNA vaccination with gp96-peptide fusion proteins induces protection against an intracellular bacterial pathogen.
    Int Immunol. 2004 Apr;16(4):597-605 PMID: 15039390
  63. Role of antiheat shock protein 60 autoantibodies in atherosclerosis.
    Lupus. 2005;14(9):742-6 PMID: 16218479
  64. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity.
    J Exp Med. 1997 Oct 20;186(8):1315-22 PMID: 9334371
  65. Heat shock proteins and toll-like receptors.
    Handb Exp Pharmacol. 2008;(183):111-27 PMID: 18071657
  66. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.
    Sci Transl Med. 2010 Dec 22;2(63):63ra94 PMID: 21178137
  67. From minichaperone to GroEL 1: information on GroEL-polypeptide interactions from crystal packing of minichaperones.
    J Mol Biol. 2000 Dec 15;304(5):873-81 PMID: 11124033
  68. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses.
    Annu Rev Immunol. 2002;20:395-425 PMID: 11861608
  69. A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice.
    Int Immunopharmacol. 2012 Feb;12(2):402-7 PMID: 22222115
  70. In vitro reconstitution of heat shock protein-peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases.
    Methods. 2004 Jan;32(1):25-8 PMID: 14624873
Article Info
Journal
Human vaccines & immunotherapeutics
Abbr.
Hum Vaccin Immunother
ISSN
2164-554X
DOI
10.4161/hv.22248
Published
2013-01-00
Epub
2012-00-29
Pages
153-61
Language
English
Region
United States
NLM ID
101572652
PMCID
PMC3667931
Subset
IM
External Links
PubMed source DOI: 10.4161/hv.22248 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2